نتائج البحث

1

Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma

المؤلفون: Daniel W. Sherbenou, Thomas G. Martin, Olivia Perez De Acha, Byron Hann, Blake T. Aftab, Megan Murnane, Yang Su, Jeffery L. Wolf, Shelby C. Bearrows, Bin Liu, Christopher R. Behrens

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 22
Clin Cancer Res

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Immunoconjugates, medicine.medical_treatment, Mice, 0302 clinical medicine, hemic and lymphatic diseases, Monoclonal, Multiple myeloma, Cancer, Tumor, Antibodies, Monoclonal, Hematology, Middle Aged, Intercellular Adhesion Molecule-1, Flow Cytometry, Antibodies, Anti-Idiotypic, Anti-Idiotypic, medicine.anatomical_structure, Oncology, 5.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Heterografts, Female, Development of treatments and therapeutic interventions, Multiple Myeloma, Biotechnology, Adult, Antibody-drug conjugate, medicine.drug_class, Oncology and Carcinogenesis, Monoclonal antibody, Article, Antibodies, Cell Line, 03 medical and health sciences, Rare Diseases, Clinical Research, In vivo, Cell Line, Tumor, medicine, Animals, Humans, Oncology & Carcinogenesis, Cell Proliferation, Aged, business.industry, Daratumumab, Immunotherapy, medicine.disease, ADP-ribosyl Cyclase 1, Orphan Drug, 030104 developmental biology, Cancer research, Bone marrow, business, Ex vivo

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c90915ca7c606383916fa2bf8e189cbTest
https://doi.org/10.1158/1078-0432.ccr-20-0400Test

2

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma

المؤلفون: Mark Raffeld, John C. Morris, John E. Janik, Thomas A. Waldmann, Donn M. Stewart, Stefania Pittaluga, Elaine S. Jaffe, Seth M. Steinberg, Cathryn C. Lee, Kamal Sharma, Thomas A. Fleisher, Maryalice Stetler-Stevenson, Deirdre O'Mahony

المصدر: Clinical Cancer Research. 23:35-42

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Phases of clinical research, Kaplan-Meier Estimate, Neutropenia, Gastroenterology, Article, Adult T-cell leukemia/lymphoma, Immunophenotyping, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Leukemia-Lymphoma, Adult T-Cell, Adverse effect, Alemtuzumab, Aged, Neoplasm Staging, Human T-lymphotropic virus 1, Leukopenia, business.industry, Middle Aged, medicine.disease, HTLV-I Infections, Surgery, Leukemia, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Retreatment, Female, Lymphocytopenia, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3956658fedf2da6e7d5dfbc4bb85ac7Test
https://doi.org/10.1158/1078-0432.ccr-16-1022Test

3

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

المؤلفون: Anton C.M. Martens, Willy A. Noort, Joost M. Bakker, Tuna Mutis, Paul W. H. I. Parren, Berris van Kessel, Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Richard W.J. Groen, Regina de Jong-Korlaar, Niels W.C.J. van de Donk, Henk M. Lokhorst

المساهمون: Hematology laboratory, Hematology, CCA - Innovative therapy

المصدر: Clinical Cancer Research, 21(12), 2802-2810. American Association for Cancer Research Inc.
Nijhof, I S, Groen, R W J, Noort, W A, van Kessel, B, de Jong-Korlaar, R, Bakker, J, van Bueren, J J L, Parren, P W H I, Lokhorst, H M, van de Donk, N W C J, Martens, A C M & Mutis, T 2015, ' Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib ', Clinical Cancer Research, vol. 21, no. 12, pp. 2802-2810 . https://doi.org/10.1158/1078-0432.CCR-14-1813Test
Nijhof, I S, Groen, R W J, Noort, W A, van Kessel, B, de Jong-Korlaar, R, Bakker, J, van Bueren, J J L, Parren, P W H I, Lokhorst, H M, van de Donk, N, Martens, A C M & Mutis, T 2015, ' Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib ', Clinical Cancer Research, vol. 21, no. 12, pp. 2802-2810 . https://doi.org/10.1158/1078-0432.CCR-14-1813Test

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_treatment, Drug Evaluation, Preclinical, Antibody-Dependent Cell Cytotoxicity/immunology, Pharmacology, Lymphocyte Activation, Bortezomib, Mice, immune system diseases, hemic and lymphatic diseases, ADP-ribosyl Cyclase 1/antagonists & inhibitors, Molecular Targeted Therapy, Lenalidomide, Multiple myeloma, Killer Cells, Natural/drug effects, Isatuximab, Drug Synergism, Middle Aged, Lymphocyte Activation/drug effects, Thalidomide, Killer Cells, Natural, medicine.anatomical_structure, Oncology, Female, Immunotherapy, Multiple Myeloma, medicine.drug, Adult, Cell Line, Tumor, medicine, Animals, Humans, Multiple Myeloma/diagnosis, Aged, Thalidomide/administration & dosage, business.industry, Antibody-Dependent Cell Cytotoxicity, Daratumumab, NATURAL-KILLER-CELLS APOPTOSIS-INDUCING LIGAND PROTEASOME INHIBITION ANTIBODY DARATUMUMAB CYTOTOXICITY COMBINATION ELOTUZUMAB MULTICENTER THALIDOMIDE EXPRESSION, medicine.disease, ADP-ribosyl Cyclase 1, Xenograft Model Antitumor Assays, Disease Models, Animal, Cancer research, Bortezomib/administration & dosage, Bone marrow, business, Ex vivo